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Abstract
Introduction: Metastasized pancreatic neuroendocrine tumors are extremely rare malignancies, especially in children.
Therefore, therapeutic options are limited, and few standardized therapy regimens exist.
Case presentation: We report a case of a 14-year-old white girl. In 2011 she was diagnosed with a metastasized,
well-differentiated pancreatic neuroendocrine tumor with expression of synaptophysin and chromogranin A. We
describe her clinical course with special attention to her individual therapeutic regimens while bringing together
several disciplines of medicine.
Conclusions: In patients such as ours, surgical intervention may be the only therapy that will lead to long-term
survival.
Keywords: Functioning pancreatic neuroendocrine tumor (F-PanNET), Islet cell tumors, Non-functioning pancreatic
neuroendocrine tumor (NF-PanNET), Pancreatic neuroendocrine tumor (PanNET), Yttrium-90 DOTATOC therapy
Introduction
Metastasized pancreatic neuroendocrine tumors (PanNETs)
are rare malignancies, especially in children and young
adolescents, for which there is no standard therapeutic
regimen. These lesions carry a poor prognosis. In this
report, we present a case of a teenage girl (14-years old at
age of first presentation) with a metastasized well-differen-
tiated PanNET. A multidisciplinary therapeutic approach
was designed by pediatric hematologists-oncologists,
pediatric surgeons, visceral surgeons, pediatric radiologists
and radio-oncologists. The primary tumor as well as its
metastases have been kept in check to date. The patient is
in good condition with little limitation of her daily
activities.
Case presentation
In 2010, a 14-year-old white girl presented to our hospital
and described having symptoms of ongoing abdominal
pain of approximately 3 weeks’ duration that was respon-
sive to analgesic medication. She reported no prior history
of nausea, vomiting, diarrhea, fever, sweating or weight
loss. Her family history has been uneventful; both parents
and a 19-year-old sister are healthy.
An abdominal ultrasound taken at that time showed
normal upper abdominal organs and multiple enlarged
lymph nodes that had previously been thought to be a
reaction to a nonspecific infection. Her pain increased
2.5 weeks later, resulting in another visit to the emer-
gency room. An abdominal magnetic resonance imaging
(MRI) scan revealed a suspicious area in the head of her
pancreas, persisting enlarged lymph nodes and unclear
liver lesions (Fig. 1 and Fig. 2).
A scheduled surgical biopsy was taken after the patient’s
overall condition worsened. In addition to increasing pain,
she lost appetite and weight. The histopathological results
of the pancreas and liver examinations revealed a metasta-
sized well-differentiated PanNET with expression of
synaptophysin and chromogranin A (CgA). The outer
membrane surface of the tumor cells expressed somato-
statin receptor 2 (SSR2), and the active proliferative rate
of Ki67 (a pathological grading marker) was 20 to 25%
(Fig. 3). The results of additional bone marrow biopsies
were unremarkable.
Extensive further diagnostic tests were done: laboratory
testing and imaging with computed tomography (CT),
68Ga-DOTA-tyrosine octreotide (68Ga-DOTATOC) posi-
tron emission tomography (PET)-CT, thoracic X-ray,
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electrocardiography and echocardiography. Her blood
work and urine analysis results are shown in Table 1.
In proximity to the previously described lesions, a
widely spreading tumor with extensive surrounding of
her superior mesenteric artery and her common hepatic
artery was detected on imaging studies. Compression of
her splenic vein and her superior mesenteric vein, as
well as obstruction of her portal vein with subsequent
intestine vein insufficiency and cholestasis, was also
diagnosed. These anatomic findings prompted us to
refrain from a (primary) curative surgical approach be-
cause of possible life-threatening circumstances.
On the basis of these diagnostic test results, an inter-
disciplinary decision was made to downsize the tumor
with an intra-arterial 4-GBq Lu-177/4-GBq yttrium
(Y)-90-DOTATOC therapy in combination with an
oral radiosensitizing chemotherapy with temozolomide
(5 days) and thalidomide (4 days) as an individual ap-
proach 2 weeks later. Because of an expected aplasia and
the main concern of weakening her overall condition, as
well as to avoid endangering the planned extended surgi-
cal procedures, cisplatin and etoposide were not used.
Despite these interventions, her condition continued
to worsen. Acute pancreatitis and biliary complications
developed. Analgesic treatment failed to relieve her pain.
As a result, surgery was indicated, despite the increased
risk for potentially fatal complications.
Surgery with tumor resection took place in the same
month. The following steps were performed: (1) ex-
tended pancreatic head resection, duodenectomy and
cholecystectomy; (2) placement of a temporary GORE-
TEX mesenteric-caval shunt and a temporary arterial
aortohepatic shunt; (3) distal gastric resection with re-
construction with gastrojejunostomy (end to side), pan-
creaticojejunostomy and hepaticojejunostomy; (4) right
hemicolectomy with terminal ileostomy and Hartmann
procedure; (5) extended soft tissue resection, including
the whole mesenteric root; (6) resection of the portal
vein with vessel interpolation by the femoral superficial
vein (from left adductor channel); (7) reconstruction of
the hepatic artery with end-to-end anastomosis on the
celiac trunk; and (8) atypical segmental liver resection of
one metastasis (segment 2/3) (Fig. 4).
Fig. 1 Axial, T2-weighted, half-Fourier single-shot turbo spin-echo hydromagnetic resonance imaging scan of the patient’s abdomen. Retroperitoneal
tissue augmentation of the dorsal pancreas is visualized with contrast enhancement (arrow)
Fig. 2 Liver metastases. a T1-weighted hydromagnetic resonance
imaging scan of the patient‘s abdomen (Gadovist coronary contrast
agent; Bayer HealthCare, Berlin, Germany) shows multiple hypodense
liver lesions (arrows). b Photograph taken during laparoscopy,
showing one of the liver metastases
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The patient recovered without major complications
and could finally be dismissed with home parenteral nu-
trition 4 weeks later.
The first DOTATOC-PET scan obtained postopera-
tively showed two remaining small, right-sided liver
metastases in segments 6 and 8.
Six weeks later, a right hemihepatectomy without touch-
ing the primarily made biliodigestive anastomosis was per-
formed as planned, followed by another DOTATOC-PET
scan 1 month later. We detected that the patient was hav-
ing a good response to therapy without signs of residual
tumor. However, splenomegaly with high DOTATOC up-
take was diagnosed. Because of the importance of the nu-
cleotide therapy with aspired further consolidating circles
and the vanished option for intra-arterial application
owing to the resective surgery, splenectomy was the only
opportunity to guarantee successful intravenous DOTA-
TOC therapy. Therefore, a splenectomy was performed.
In the same procedure, the ileostomy was taken down.
The next intravenous Lu-177/DOTATOC therapy was
done. In the same month (6 months after the histo-
pathological specimen results), an oral tyrosine kinase
inhibitor medication with sunitinib was initiated. A
follow-up examination 2 months later with DOTATOC-
PET and MRI scans was unremarkable. The patient re-
covered in a rehabilitation unit without being dependent
on parenteral nutrition any longer.
Unfortunately, the next follow up DOTATOC-PET
scan taken 1 year later showed increased uptake in her
para-aortal lymph nodes and left inguinal soft tissue, so
metastases of the primary tumor were expected (Fig. 5).
Surgical extirpation of the suspicious left-sided inguinal
lesion confirmed this hypothesis. The same endocrine
malignant tumor cells could be seen (Ki-67: 30%; SSR2/
DOTATOC-positive). Consequently, a para-aortic lymph-
adenectomy was performed.
Afterward, the patient additionally received intravenous
Y-90-DOTATOC therapy. Despite those interventions, the
Fig. 3 Histopathological findings. Microscopic aspects of primary tumor (a) and liver metastasis (b through f). As shown in hematoxylin and
eosin-stained sections (a, b), the tumor displays an organoid growth pattern with predominant trabecular formations of atypical epithelial cells.
Nuclei show only little to moderate pleomorphism, and the cytoplasm is well formed and sometimes contains vacuoles. On immunohistochemical
examination, tumor cells show positivity for the neuroendocrine markers chromogranin A (c) and synaptophysin (d). Ki67 staining (e) reveals high
proliferative activity. The tumor cells display membranous positivity of the somatostatin receptor 2a (f)
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next DOTATOC-PET scan still showed suspicious para-
aortic lymph nodes. Repeat resection of the para-aortic
lymph nodes was performed, followed by intravenous Ac-
225-DOTATOC therapy.
Owing to the stable oncologic situation and regarding
the cumulative dose of radioactivity, with its increasing
risk of chronic nephrotoxicity and bone marrow toxicity,
no further nuclear medical therapy was planned as of
this writing. Meanwhile, somatostatin (SST) analogue
therapy with Somatuline Autogel® 60mg (IPSEN, Signes,
France), a long-lasting lanreotide option (injected sub-
cutaneously once per month), as a non-radioactive
blockade of tumor receptors was started to achieve
remission.
The follow-up screening with DOTATOC-PET/CT 1.5
years after her first diagnosis indicated nonspecific
nuclide uptake in her right breast and in one left-sided
inguinal lymph node, as well as new high nuclide uptake
in the right temporobasal part of her brain. Subsequent
MRI of her brain confirmed a noticeable lesion raising
strong suspicion of cranial metastases. Those lesions
were irradiated with the patient in stereotactic position-
ing, and a good response was observed on the next MRI.
In another surgical intervention, the left-sided inguinal
lymph node was removed, which was pathologically
confirmed as a metastasis of the primary tumor.
The patient reports that she is unaffected and repeat
imaging is scheduled at short intervals to ensure regular
follow-up.
The case presentation is summarized in Fig. 6.
Discussion
PanNETs are rare pancreatic neoplasms compared with
their more common exocrine counterparts. Arising from
the pancreatic islets of Langerhans, they are also called
islet cell tumors. They occur in 1 to 2 of 100,000 cases
per year, accounting for less than 2% of all digestive ma-
lignant tumors and less than 1% of endocrine tumors.
PanNETs represent approximately 3% of primary pan-
creatic neoplasms. Although they may manifest at any
age, they most often occur in the fourth to sixth decades
of life [1, 2].
Classically, PanNETs are divided into two groups:
functioning pancreatic neuroendocrine tumors (F-Pan-
NETs) and non-functioning pancreatic neuroendocrine
tumors (NF-PanNETs). F-PanNETs are hormonally
active and may lead to earlier diagnosis because of their
hormone-related symptoms. Common types are insuli-
noma and gastrinoma, and rare types are VIPoma
(vasoactive intestinal peptide), glucagonoma or soma-
tostatinoma. For example, insulinomas often present
with hypoglycemic symptoms and low blood glucose
levels and are reversible after glucose intake; gastrino-
mas present with diarrhea, hypergastrinemia, gastric
Table 1 Laboratory values
Test Value Normal range
Glutamic oxaloacetic transaminase 277U/L <35U/L
Glutamic pyruvic transaminase 342U/L <35U/L
Alkaline phosphatase 233U/L 55 to 105U/L
γ-Glutamyl transferase 339U/L <40U/L
Total bilirubin 0.7mg/dl <1mg/dl
Conjugated bilirubin 0.26mg/dl <0.3mg/dl








AFP, α-fetoprotein; β-hCG, Human chorionic gonadotropin, β-subunit; CgA,
Chromogranin A; NSE, Neuron-specific enolase
Fig. 4 Situs. a Intraoperative photograph of temporal placement of a mesenteric-caval GORE-TEX (*) shunt (GORE Medical, Flagstaff, AZ, USA) and
a temporal arterial aortohepatic shunt (+). b Intraoperative photograph taken after extended resection
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acid hypersecretion and peptic ulcer diathesis, known
as Zollinger–Ellison syndrome [2].
Although NF-PanNETs secrete a number of sub-
stances such as chromogranin, synaptophysin, neuron-
specific enolase, pancreatic polypeptide and ghrelin, in
contrast to F-PanNETs they do not present clinically
with hormone-related symptoms. As a result, they often
present later in the course of the disease with symptoms
such as abdominal pain (35 to 75%), weight loss (20 to
35%) and anorexia and nausea (45%). Less frequent
signs include obstructive jaundice (17 to 50%), intra-
abdominal hemorrhage (4 to 20%) or a palpable mass
(7 to 40%). Symptoms may also be attributable to
metastatic disease, which occurs in, for example, the
liver or bones (between 32 and 73% of cases are
metastatic at diagnosis). NF-PanNETs may occur in
association with the multiple endocrine neoplasia type 1
syndrome, von Hippel–Lindau syndrome, neurofibroma-
tosis type 1 and tuberous sclerosis [2–4]. Genetic analyses
were not performed in our patient. Nevertheless, consider-
ing the association of PanNETs with familial syndromes,
this is an important issue, especially in young patients
with PanNETs.
There are different possibilities for a diagnostic strat-
egy: abdominal ultrasound, endoscopic ultrasound, ab-
dominal CT, abdominal MRI, SST receptor scintigraphy,
68Ga-DOTATOC-PET/CT with a higher spatial reso-
lution than scintigraphy, fine-needle aspiration cytology
and/or biopsy, and laboratory tests with CgA [5, 6].
The 2010 World Health Organization classification sys-
tem distinguishes between poorly differentiated neuroen-
docrine carcinomas (NECs) versus well-differentiated
neuroendocrine tumors (NETs). All NECs are graded G3
with a Ki67 index greater than 20%. NETs are divided into
G2 grade with a Ki67 index of 3 to 20% and G1 grade with
a Ki67 index of 2% or less. Most pancreatic non-
functioning (NF) neuroendocrine neoplasms are well dif-
ferentiated (that is, NETs); NF-NECs are uncommon [3].
In the present case, our patient has been diagnosed with
a well-differentiated NF-NEC, despite a Ki67 index of 20 to
25%, with a TNM classification of ypT3, ypN1(8/31),
ypM1(liver) according to European Neuroendocrine Tumor
Society consensus guidelines. Poorly differentiated pancre-
atic neuroendocrine neoplasms are characterized by their
aggressive tumor biology, absence of SST receptors and
poor prognosis.
Fig. 5 Axial computed tomographic scan without contrast agent displaying left inguinal soft tissue. Suspicious hyperdense, irregularly shaped
lesion (arrow) with a diameter of approximately 8mm in the left inguinal soft tissue
Fig. 6 Timeline of the patient’s history. DOTATOC 68Ga-DOTA-tyrosine octreotide, LK lymph nodes
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Clinical management involves a multidisciplinary ap-
proach, but surgery remains the only curative therapy for
early-stage disease. It represents the treatment of choice
in cases of localized PanNETs, including typical and atyp-
ical resections. In particular, radical resection of pancreatic
tumors is associated with favorable long-term outcomes
in children and adolescents [7]. Palliative surgery of locally
advanced PanNETs is justified in selected patients. For pa-
tients with metastatic NF tumors, surgery of the primary
tumor is recommended only for G1 and G2.
Further treatment options are SST analogues (for ex-
ample, octreotide or lanreotide) for subgroups of patients
with slowly progressive, low proliferative PanNETs;
systemic chemotherapy (such as streptozotocin, 5-
fluorouracil or doxorubicin) in all PanNETs and NECs;
peptide radionuclide receptor therapy (PRRT; SST an-
alogues labeled with β-emitting radionuclides such as
Y-90-DOTATOC) for patients with NETs with the pres-
ence of SST receptors; hepatic artery embolization or che-
moembolization in patients with liver metastases who are
not candidates for surgical resection; radiofrequency abla-
tion in patients with unresectable metastases more than 5
to 7cm in diameter; radiotherapy using high-energy
isotope treatment for patients with inoperable disease;
immunotherapy (for example, interferon, dendritic cell
immunotherapy), which may be used to offer hormone-
related symptom control to patients in whom SST
analogue therapy has failed; and molecular targeted ther-
apy (including anti-epidermal growth factor receptor or
anti-vascular endothelial growth factor receptor therapy
such as sunitinib) for individual attempts and future
options [1, 3, 8].
In our patient, a primary curative surgical approach
could not be used, owing to the anatomic findings of the
spreading tumor. As the initial PRRT (with Y-90-
DOTATOC) combined with chemotherapy (temozolo-
mide and thalidomide) failed [9], surgery convincingly
emerged as the patient’s last chance of potentially
surviving. Successful treatments to that point of the
patient’s medical history involved different therapy op-
tions mainly combined repeated cycles of intravenous
DOTATOC therapy with different surgical attempts, in-
cluding resection of metastases and radiotherapy of the
brain metastases. As shown, the patient’s best chance of
surviving is an individual approach combining all thera-
peutic options, and, in our patient, radical surgery was the
most important part.
The median overall survival for patients with NF-
PanNETs is reportedly approximately 38 months. Pa-
tients with distant metastases have a median survival of
23 months, as compared with 70 to 124 months for
those with localized disease [10–12]. Our patient is
living and has a good quality of life approximately 42
months since the time of her first diagnosis.
Conclusions
PanNETs are rare tumors that often invade adjacent or-
gans and anatomic structures, causing symptoms. Be-
cause of its rarity, randomized controlled studies have
not been done and current treatment recommendations
are based primarily on case series and individual treat-
ment approaches. So far, total resection of the tumor is
the treatment of choice and seems to be associated with
the best prognosis, particularly when accompanied by
further different therapies as mentioned above. Unre-
sectable or partially resectable tumors and recurrent tu-
mors can be treated with local and/or systemic radiation
(PRRT) and/or adjuvant chemotherapy to downsize the
tumor. Even then, surgery seems to be an important
intervention option, which gives the patient relief from
symptoms.
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